| 2026-04-02 | 1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds | StockStory | Strong Negative (-0.6998) |
| 2026-03-29 | A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness | Simply Wall St. | Neutral (0.0197) |
| 2026-03-27 | RadNet, Evolent Health, Illumina, Charles River Laboratories, and Repligen Stocks Trade Down, What You Need To Know | StockStory | Negative (-0.2193) |
| 2026-03-27 | 1 Value Stock on Our Buy List and 2 We Turn Down | StockStory | Neutral (-0.0664) |
| 2026-03-23 | Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? | Barchart | Strong Negative (-0.9127) |
| 2026-03-20 | Why Is Charles River (CRL) Down 6.8% Since Last Earnings Report? | Zacks | Strong Negative (-0.9612) |
| 2026-03-12 | 3 Reasons CRL is Risky and 1 Stock to Buy Instead | StockStory | Neutral (-0.0169) |
| 2026-03-11 | Locus Cell, Taiwan-Based Cell and Gene Therapy CDMO, Signs MoU with Charles River at APAC Biomanufacturing Leadership Summit | PR Newswire | Strong Positive (0.7517) |
| 2026-03-11 | IQVIA Expands In Vitro Discovery Footprint As Shares Face Pressure | Simply Wall St. | Strong Positive (0.8781) |
| 2026-03-11 | Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More | 24/7 Wall St. | Strong Negative (-0.7717) |